PPC 5: ELECTRONIC PRESCRIBING Element B: Electronic Decision Support - Safety

EHS allows CHC-B' providers to write prescriptions using electronic prescription reference information at the point of care. CHC-B uses all 15 kinds of alerts and information and, therefore, scores 100% for using 8 or more of the listed alerts for PCMH. The following screen shots show examples of the references available within EHS.

Pharmacology Allerg Language C English (osing Spanish	Interactions La	ctation Pregna	ancy Patient	Education Sid	e Effects War	nings The	rapeutic Dupl
What other dru	gs will affe	ct amoxicillin	17					
Before	taking amo:	cicillin, tell your	r doctor if you	are using a	ny of the follow	ving drugs:		
-metho	trexate (Rh	eumatrex, Trex	all);					
	necid (Bene	<i>,</i> ,	_					
	~ `	as Bactrim or	, ,.	-1	and a state of the second		<i>(</i>	- Marcin
		as azithromyc in), or telithrom			ycin (Biaxin),	erythromycin	(E.E.S., t	z-Mycin,
 a tetra 	acycline ant	ibiotic such as	demeclocycli	ne (Declom				
	nycın), mını cin, Tetraca	ocycline (Dynau n)	cin, Minocin, S	Solodyn, Ve	ctrin), or tetra	cycline (Brod	spec, Pan	mycin,
,		plete and there	e may be othe	r drugs that	can interact v	vith amoxicill	in. Tell you	ur doctor
		ription and over						
	products, ar (our doctor.	nd drugs prescr	ibed by other	doctors. Do	not start usin	ig a new med	ication with	nout

Item 1: Drug-Drug Interaction General

Item 2: Drug-Drug Interaction Specific

Drug Interaction for carvedilol

DRUG INTERACTIONS:

carvedilol - albuterol [Severity Major]

GENERALLY AVOID: Beta blockers may antagonize the effects of bronchodilator beta-adrenergic agonists, which may result in life-threatening bronchospasm. The mechanism is increased airway resistance and inhibition of beta-agonistinduced bronchodilation due to beta-2-adrenergic blockade. Ophthalmically applied beta blockers undergo some systemic absorption and may also interact. Propranolol has been used in the treatment of albuterol overdose.

MANAGEMENT: This combination should generally be avoided. If no alternative exists, small doses of a B-1 selective betablocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, or metoprolol) may be preferable; however, extreme caution is advised and patients' respiratory status should be closely monitored. Non-selective beta-blockers are generally considered contraindicated in patients with obstructive airways disease.

Accept Medication

Decline Medication

_ 🗆 X

Item 3: Drug-Disease Interaction General

Drug Information for ethinyl estradiol-norgestimate	×
Pharmacology Allergies Dosing Interactions Lactation Pregnancy Patient Education Side Effects Warnings Therapeutic Duplic	ation
Language © English © Spanish	
What is the most important information I should know about ethinyl estradiol and norgestimate?	
• Do not use this medication if you have any of the following conditions: a history of stroke or blood clot, circulation problems, a hormone-related cancer such as breast or uterine cancer, abnormal vaginal bleeding, liver disease or liver cancer, migraine headaches, or a history of jaundice caused by birth control pills.	
 You may need to use back-up birth control, such as condoms or a spermicide, when you first start using this medication. Follow your doctor's instructions. 	
• Taking hormones can increase your risk of blood clots, stroke, or heart attack, especially if you smoke and are older than 35.	
 Some drugs can make birth control pills less effective, which may result in pregnancy. Tell your doctor about all the prescription and over-the-counter medications you use, including vitamins, minerals and herbal products. Do not start using a new medication without telling your doctor. 	
	-
Print Close	

Item 4: Drug-Disease Interaction Specific

C	Drug Interaction for glipiZIDE
	DRUG-DISEASE INTERACTIONS
	Severity - Major, Plausibility - High
	Sulfonylureas are metabolized in the liver, and their metabolites (some with pharmacologic activity) are excreted in the urine and feces. Patients with impaired liver and/or renal function treated with sulfonylureas may be exposed to higher serum drug concentrations, which can increase the potential for severe hypoglycemic episodes induced by these agents. In the presence of hepatic impairment, gluconeogenic capacity may also be diminished, further compounding the risk. Therapy with sulfonylureas should be administered cautiously in patients with liver and/or renal disease. Reduced dosages and longer intervals between dosage adjustments may be required. Hypoglycemia, if it occurs during treatment, may be prolonged in these patients because of slowed metabolism and/or excretion of the drugs.
	Severity - Major, Plausibility - Moderate
	ОК

Item 5: Drug-Allergy Interaction General

Drug Information for amoxicillin	×
Pharmacology Allergies Dosing Interactions Lactation Pregnancy Patient Education Side Effects Warnings Therapeutic Duplica	ation
Language © English © Spanish	_
amoxicillin	
Pronunciation: am OX i sil in Brand: Amoxil, Amoxil Pediatric Drops, Moxatag, Trimox	
Brand, Alloxi, Alloxi Feddaut, Drops, Moxalag, Tilliox	
What is the most important information I should know about amoxicillin?	
Do not use this medication if you are allergic to amoxicillin or to any other penicillin antibiotic, such as ampicillin (Omnipen, Principen), dicloxacillin (Dycill, Dynapen), oxacillin (Bactocill), penicillin (Beepen- VK, Ledercillin VK, Pen-V, Pen-Vee K, Pfizerpen, V-Cillin K, Veetids), and others.	
 Before using amoxicillin, tell your doctor if you are allergic to cephalosporins such as Ceclor, Ceftin, Duricef, Keflex, and others. Also tell your doctor if you have asthma, liver or kidney disease, a bleeding or blood clotting disorder, mononucleosis (also called "mono"), or any type of allergy. 	
Amoxicillin can make birth control pills less effective, which may result in pregnancy. Before taking amoxicillin, tell your doctor if you use birth control pills.	-
Print Close	

- 1

Item 6: Drug-Allergy Interaction Specific

	IONS:				
This patient is aller	gic to penicillin. Ar	noxicillin is a(n) pen	cillin and may show	allergic cross-reactivity to	penicillin.

Item 7: Drug-Patient History

The use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens. The frequency and/or severity of attacks may be increased during beta-blocker therapy. In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.

ΟK

•

Item 8: Appropriate dosing based on general information

i	Rediatric Dosing Calculator for amoxicillin Age: 15 Yrs	×
	Pediatric Dosing Suggestions:	_
	OTITIS MEDIA:	
:	4 weeks to 3 months: 20 to 30 mg/kg/day in divided doses every 12 hours 4 months to 12 years: 20 to 50 mg/kg/day in divided doses every 8 to 12 hours; acute otitis media due to highly resistant strains of Streptococcus pneumonia may require doses of 80 to 90 mg/kg/day orally divided into 2 equal doses 12 hours apart	
•	SKIN OR SOFT TISSUE INFECTION:	
:	4 weeks to 3 months: 20 to 30 mg/kg/day in divided doses every 12 hours 4 months to 12 years: 20 to 50 mg/kg/day in divided doses every 8 to 12 hours; acute otitis media due to highly resistant strains of Streptococcus pneumonia may require doses of 80 to 90 mg/kg/day orally divided into 2 equal doses 12 hours apart	
1	URINARY TRACT INFECTION:	
i	4 weeks to 3 months: 20 to 30 mg/kg/day in divided doses every 12 hours 4 months to 12 years: 20 to 50 mg/kg/day in divided doses every 8 to 12 hours; acute otitis media due to highly resistant strains of Streptococcus pneumonia may require doses of 80 to 90 mg/kg/day orally divided into 2 equal doses 12 hours apart	
	JPNEUMONIA:	•

Item 9: Appropriate dosing calculated for the patient

🖷, Pediatric Dosing Calcul	ator for amoxicillin	Age: 7 Yrs,	1 Mos				×
Pediatric Dosing Suggestions:							
BACTERIAL ENDOCARDITI	6 PROPHYLAXIS:				_		_
50 mg/kg orally as a single do	ose 1 hour prior to procedure						100
Amoxicillin is not appropriate a endocarditis, and those who l parenteral antimicrobial therap	have had surgically construc						
ANTHRAX PROPHYLAXIS:							
80 mg/kg/day divided into eo Maximum dose: 500 mg/dose		y every 8 hours					
Oral amoxicillin is not conside course after 10 to 14 days of							
CUTANEOUS BACILLUS AN	THRACIS:						
Treatment for confirmed case	s of cutaneous Bacillus anth	nracis infection: 80 m	g/kg/day divided into equal	doses ad	ministe	ered oral	lly every 8 🗾
2							
		1	mg/kg/day				ОК
		x Weight:	kg	7	8	9	Cancel
Frequency: 3 times a day	•	x Every	8 hours/24	4	5	6	
	Display On SIG C	Amount			-	<u> </u>	
	Display on Sig C		mg	<u> </u>	2	3	
		1	25 mg/ml	0		C	
	Display on SIG 📀	Quantity	mi	-			
odinine. III ma tablet	L tablel orally or	ueb e eou	ЧПТАБІЛІ	_			

Item 10: Therapeutic Monitoring (Drug-Lab Alert)

	I BY B /	
D	Drug Information for warfarin	×
	Pharmacology Allergies Dosing Interactions Lactation Pregnancy Patient Education Side Effects Warnings Therapeutic Duplica	ation
	The most serious risks associated with warfarin are hemorrhage in any organ or tissue and, less frequently (less than 0.1%), necrosis and/or gangrene of skin and other tissues. Necrosis and hemorrhage have in some cases been reported to result in death or permanent disability. Necrosis usually appears within a few days of the start of anticoagulant therapy and appears to be associated with local thrombosis. Treatment through debridement or amputation of the affected tissue, limb, breast or penis has been reported in severe cases of necrosis. Careful diagnosis is needed to determine whether necrosis is caused by an underlying disease. Warfarin therapy should be discontinued when it is suspected to be the cause of developing necrosis and heparin therapy may be considered for anticoagulation. No treatment for necrosis has been considered uniformly effective, although various treatments have been attempted. These and other risk factors associated with anticoagulant therapy must be weighed against the risk of thrombosis or embolization in untreated patients.	
	It cannot be emphasized too strongly that anticoagulation treatment of each patient is a highly individualized matter. Werfarin, a percent borepoutio range (index) drug may be effected by factors such as other drugs and distant witemin K. Dosage should be maintained by periodic determinations of prothrombin time (PT)/International Normalized Ratio (INR) or other suitable coagulation tests. Determinations of whole blood clotting and bleeding times are not effective measures for control of anticoagulation therapy. Heparin prolongs the one-stage PT.	
	Caution should be used when warfarin is administered in any situation where added risk of hemorrhage, necrosis, and/or gangrene is present.	
	The risk of bleeding may be increased in hemodialysis patients receiving warfarin treatment. The benefit of therapy should be fully assessed prior to treating such patients with warfarin.	•

Item 11: Duplication of a drug in a therapeutic class – General

	Current	Print E	Rx	Interactions	1		1	Med	ications Recor	nciled				
Delete	Renew	Disconti	nue	Details	Drug	nto	Sign Off	Ed	t Edit Log	Req H	Map	WOR	Ph	armacy
rescribed	Medi	cation N	Sig			R	Prescriber		Expiration	Pharmacy	Pharma	cv P	Ren	Ma(🔺
10/27/2		100 u	SIG:	20 units sub	ocuta	11	(+	10/21/2011	W.	I.		•	
10/27/2		Log Flex		subcutaneo		11	L		10/21/2011	W			•	
09/27/2	010 Coun	nadin 5	SIG:	orally once	a da	10	C		N/A	S	-	++		1.00
ug Infor	mation fo	warfarin				10.120		10	2	L		222		
Pharmac	ology Ale	igies Dos	ina	Interactions	Lactat	ion	Pregnancy	Patie	ent Education	Side Effec	ts Warnin	igs The	Hapeuti	ic Duplicat
	1-1-1-1								1					
active o	rder(s) to	rwanann	exist	and may r	epres	enttr	rerapeutic	anb	lication.					

Drug Interaction for albuterol		
·		
THERAPEUTIC DUPLICATION:		
active order(s) for albuterol exist and may represent therapeutic duplication	n.	
		D F H F F
	Accept Medication	Decline Medication

Item 12: Duplication of a drug in a therapeutic class – Specific

Item 13: Drugs to be avoided in the elderly – General

Drug Information for cyclobenzaprine
Pharmacology Allergies Dosing Interactions Lactation Pregnancy Patient Education Side Effects Warnings Therapeutic Duplication
The manufacturer reports that cyclobenzaprine is contraindicated for use in patients in the acute recovery phase of myocardial infarction. The manufacturer also reports that cyclobenzaprine is contraindicated for use in patients with arrhythmias, heart block, conduction disturbances, congestive heart failure or hyperthyroidism.
Current use of monoamine oxidase inhibitors or use of monoamine oxidase inhibitors within the previous 14 days is a contraindication to the use of cyclobenzaprine.
Cyclobenzaprine (like tricyclic antidepressants) should not be discontinued abruptly in patients who have received the medication for long periods or at high doses. Abrupt discontinuation may theoretically result in symptoms of withdrawal.
Because most muscle relaxants and antispasmodic drugs can cause anticholinergic adverse events, sedation, and weakness, and because their effectiveness at doses tolerated by elderly people is questionable, cyclobenzaprine meets the Beers criteria as a medication that is potentially inappropriate for use in older adults.
Cyclobenzaprine may impair the mental abilities necessary for potentially hazardous tasks such as driving or operating machinery.
Patients should be warned that the CNS depressant effects of cyclobenzaprine may be increased by the concurrent use of other CNS depressants, including alcohol.

Medication Summary Medications Reconciled Current Print ERx Interactions Drug Interaction for meloxicam No Known Current Meds Severity - Major, Plausibility - High No Severity - Major, Plausibility - High Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause gastrointestinal mucosal damage, the risk of which appears to be related to both dosage and duration of therapy. Serious GI toxicity such as bleeding, ulceration and perforation can develop at any time, with or without warning symptoms, and occurs in approximately 1% of patients treated for 3 to 6 months and 2% to 4% of patients treated for one year. These trends continue with longer duration of use, although short-term therapy is not without risk. While agents that selectively inhibit cyclooxygenase-2 (i.e., CDX-2 inhibitors) are generally thought to be associated with a reduced risk of GI toxicity compared to conventional NSAIDs, they have not been proven risk-free. In addition, there is evidence that CDX-2 inhibitors may delay healing of gastric ulcers, and likely to the same extent as traditional NSAIDs. Thus, therapy with all NSAIDs, including CDX-2 inhibitors, should be prescribed cautiously in patients with a history of peptic ulcer disease and/or gastrointestinal bleeding. Patients with such a history who use NSAIDs have a great than 10-fold increased risk for developing a GI bleed compared to patients with neither of these risk factors. Caution is also advised if NSAIDs are prescribed to patients with other risk	ate: 11/02/2010	Gender/Age: F/60 March	Chart #: LC	Work Ph:	No In	isurance
Current Print ERx Interactions Drug Interaction for meloxicam Image: No Known Current Meds Severity - Major, Plausibility - High Severity - Major, Plausibility - High Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause gastrointestinal mucosal damage, the risk of which appears to be related to both dosage and duration of therapy. Serious GI toxicity such as bleeding, ulceration and perforation can develop at any time, with or without warning symptoms, and occurs in approximately 1% of patients treated for 3 to 6 months and 2% to 4% of patients treated for one year. These trends continue with longer duration of use, although short-term therapy is not without risk. While agents that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) are generally thought to be associated with a reduced risk of GI toxicity compared to conventional NSAIDs, they have not been proven risk-free. In addition, there is evidence that COX-2 inhibitors may delay healing of gastric ulcers, and likely to the same extent as traditional NSAIDs. Thus, therapy with all NSAIDs, including COX-2 inhibitors, should be prescribed cautiously in patients with a history of peptic ulcer disease and/or gastrointestinal bleeding. Patients with such a history who use NSAIDs have a greater than 10-fold increased risk for developing a GI bleed compared to patients with neither of these risk factors. Caution is also advised if NSAIDs are prescribed to patients with other risk			PBM M	edication History	Medication History	Vitals Op
Severity - Major, Plausibility - High Nonsteroidal anti-inflammatory drugs (NSAID's) can cause gastrointestinal mucosal damage, the risk of which appears to be related to both dosage and duration of therapy. Serious GI toxicity such as bleeding, ulceration and perforation can develop at any time, with or without warning symptoms, and occurs in approximately 1% of patients treated for 3 to 6 months and 2% to 4% of patients treated for one year. These trends continue with longer duration of use, although short- term therapy is not without risk. While agents that selectively inhibit cyclooxygenase-2 (i.e., CDX-2 inhibitors) are generally thought to be associated with a reduced risk of GI toxicity compared to conventional NSAID's, they have not been proven risk-free. In addition, there is evidence that CDX-2 inhibitors may delay healing of gastric ulcers, and likely to the same extent as traditional NSAID's. Thus, therapy with all NSAID's, including CDX-2 inhibitors, should be prescribed cautiously in patients with a history of peptic ulcer disease and/or gastrointestinal bleeding. Patients with such a history who use NSAID's have a greater than 10-fold increased risk for developing a GI bleed compared to patients with neither of these risk factors. Caution is also advised if NSAID's are prescribed to patients with other risk	1 1	i and				
term therapy is not without risk. While agents that selectively inhibit cyclooxygenase-2 (i.e., CDX-2 inhibitors) are generally thought to be associated with a reduced risk of GI toxicity compared to conventional NSAIDs, they have not been proven risk-free. In addition, there is evidence that CDX-2 inhibitors may delay healing of gastric ulcers, and likely to the same extent as traditional NSAIDs. Thus, therapy with all NSAIDs, including CDX-2 inhibitors, should be prescribed cautiously in patients with a history of peptic ulcer disease and/or gastrointestinal bleeding. Patients with such a history who use NSAIDs have a greater than 10-fold increased risk for developing a GI bleed compared to patients with neither of these risk factors. Caution is also advised if NSAIDs are prescribed to patients with other risk.	Drug Interac	tion for meloxicam				_ 🗆 🗵
factors such as oral corticosteroid or anticoagulant use, alcohol use, smoking, older age, and poor general health status.	term therapy is generally thou been proven ri to the same ex prescribed cau such a history patients with n	nti-inflammatory drugs (NSAIDs oth dosage and duration of the time, with or without warning s to 4% of patients treated for o not without risk. While agents ght to be associated with a redi sk-free. In addition, there is ev tent as traditional NSAIDs. The tiously in patients with a history who use NSAIDs have a great either of these risk factors. Can	rapy. Serious GI toxicity su symptoms, and occurs in ap ne year. These trends con that selectively inhibit cyck uced risk of GI toxicity comp idence that CDX-2 inhibitor: us, therapy with all NSAIDs of peptic ulcer disease and of peptic ulcer disease and er than 10-fold increased ris ution is also advised if NSAI	ch as bleeding, uld proximately 1% of p tinue with longer d ooxygenase-2 (i.e., pared to conventio s may delay healing , including COX-2 i d/or gastrointesting a IDs are prescribed	eration and perforation patients treated for 3 to uration of use, although COX-2 inhibitors) are nal NSAIDs, they have g of gastric ulcers, and nhibitors, should be a bleeding. Patients wi GI bleed compared to to patients with other ri	i can 6 n short- likely th

Item 14: Drugs to be avoided in the elderly – Specific

Item 15: Patient Appropriate Medication Information

nguage	
English C Spa	ish
	albuterol
	Pronunciation: al BYOO teh rall
	Brand: Proventil, Proventil Repetabs, Ventolin, Volmax
What is the most im	portant information I should know about albuterol?
amount of ar	al attention if you notice that you require more than your usual or more than the maximum y asthma medication in a 24-hour period. An increased need for medication could be an a serious asthma attack.
What is albuterol?	
	ks by relaxing muscles in the airways to improve breathing.
	ks by relaxing muscles in the airways to improve breathing. Ised to treat bronchospasm (wheezing, shortness of breath) associated with reversible